Mouse models of peritoneal carcinomatosis to develop clinical applications
Á Bella, CA Di Trani, M Fernández-Sendin… - Cancers, 2021 - mdpi.com
Simple Summary Peritoneal carcinomatosis mouse models as a platform to test, improve
and/or predict the appropriate therapeutic interventions in patients are crucial to providing …
and/or predict the appropriate therapeutic interventions in patients are crucial to providing …
Complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: risk factors for ICU admission …
S Malfroy, F Wallet, D Maucort-Boulch, L Chardonnal… - Surgical oncology, 2016 - Elsevier
Background and objectives For patients suffering from peritoneal carcinomatosis,
cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is the only …
cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is the only …
Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared …
R Mirnezami, AM Mehta, K Chandrakumaran… - British journal of …, 2014 - nature.com
Background: Colorectal cancer peritoneal metastasis (CPM) confers an exceptionally poor
prognosis, and traditional treatment involving systemic chemotherapy (SC) is largely …
prognosis, and traditional treatment involving systemic chemotherapy (SC) is largely …
Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal …
W Jimenez, A Sardi, C Nieroda, M Sittig… - Annals of surgical …, 2014 - Springer
Background Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy
(HIPEC) has survival benefit in the treatment of selected patients with peritoneal …
(HIPEC) has survival benefit in the treatment of selected patients with peritoneal …
HIPEC-induced acute kidney injury: a retrospective clinical study and preclinical model
LF Liesenfeld, B Wagner, HC Hillebrecht… - Annals of Surgical …, 2022 - Springer
Background Hyperthermic intraperitoneal chemotherapy (HIPEC) combined with
cytoreductive surgery (CRS) is the treatment of choice for selected patients with peritoneal …
cytoreductive surgery (CRS) is the treatment of choice for selected patients with peritoneal …
Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy
EIL Sin, CS Chia, GHC Tan, KC Soo… - International Journal of …, 2017 - Taylor & Francis
Background: Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (CRS-
HIPEC) prolongs survival in patients with metastatic peritoneal disease. We look at the …
HIPEC) prolongs survival in patients with metastatic peritoneal disease. We look at the …
[HTML][HTML] Inflammatory response and toxicity after pressurized intraperitoneal aerosol chemotherapy
HT Farinha, F Grass, I Labgaa, B Pache… - Journal of …, 2018 - ncbi.nlm.nih.gov
Background: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is a novel mode of
intraperitoneal (IP) drug delivery claiming high IP tissue concentrations with low systemic …
intraperitoneal (IP) drug delivery claiming high IP tissue concentrations with low systemic …
[HTML][HTML] Postoperative complications and critical care management after cytoreduction surgery and hyperthermic intraperitoneal chemotherapy: A systematic review of …
AS Wajekar, SL Solanki, VP Patil - World Journal of Critical Care …, 2022 - ncbi.nlm.nih.gov
BACKGROUND Cytoreductive surgery (CRS) and hyperthermic intraperitoneal
chemotherapy (HIPEC) is a comprehensive treatment option performed for peritoneal …
chemotherapy (HIPEC) is a comprehensive treatment option performed for peritoneal …
Predictors of anastomotic failure after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: does technique matter?
JT Wiseman, C Kimbrough, EW Beal, MY Zaidi… - Annals of surgical …, 2020 - Springer
Background Anastomotic failure (AF) after cytoreductive surgery (CRS) with hyperthermic
intraperitoneal chemotherapy (HIPEC) remains a dreaded complication. Whether specific …
intraperitoneal chemotherapy (HIPEC) remains a dreaded complication. Whether specific …
Predictive risk factors of acute kidney injury after cytoreductive surgery and cisplatin-based hyperthermic intra-peritoneal chemotherapy for ovarian peritoneal …
MA Angeles, F Quenet, P Vieille, L Gladieff… - International Journal of …, 2019 - ijgc.bmj.com
Objective The aim of our study was to assess the incidence and identify the predictive risk
factors of acute kidney injury after cytoreductive surgery and cisplatin-based hyperthermic …
factors of acute kidney injury after cytoreductive surgery and cisplatin-based hyperthermic …